Randomized trial of immunosuppressive regimens in renal transplantation

Giselle Guerra, Gaetano Ciancio, Jeffrey Gaynor, Alberto Zarak, Randolph Brown, Lois Hanson, Junichiro Sageshima, David Roth, Linda J Chen, Warren Kupin, Lissett Tueros, Phillip Ruiz, Alan Livingstone, George W Burke

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The optimal long-term regimen for immunosuppression for kidney transplant recipients is unknown. We conducted a randomized trial involving 150 kidney transplant recipients to compare tacrolimus/sirolimus, tacrolimus/mycophenolate mofetil (MMF), and cyclosporine/sirolimus. All patients received daclizumab induction and maintenance corticosteroids. Median follow-up was 8 yr post-transplant. Acute rejection (AR) occurred significantly less often among those treated with tacrolimus/MMF (12%) than among those treated with tacrolimus/sirolimus (30%) or cyclosporine/sirolimus (28%). Mean estimated GFR was consistently higher in the tacrolimus/MMF arm, especially after controlling for donor age in a multivariable model during the first 36 mo (P ≲ 0.008). The rate of dying with a functioning graft was significantly higher among those treated with tacrolimus/sirolimus (26%) than among those treated with tacrolimus/ MMF (12%) or cyclosporine/sirolimus (4%). We did not observe significant differences in actuarial graft survival at 8 yr post-transplant between the groups. Patient noncompliance seemed responsible for 45% (13/29) of observed graft failures, with 11 of these occurring after 36 mo. Significantly more viral infections, protocol violations, and need for antilipid therapy occurred among patients receiving sirolimus, but we did not observe differences between the groups with regard to infections requiring hospitalization or new-onset diabetes. Taken together, these results suggest that maintenance therapy with tacrolimus/MMF is more favorable than either tacrolimus/sirolimus or cyclosporine/sirolimus.

Original languageEnglish
Pages (from-to)1758-1768
Number of pages11
JournalJournal of the American Society of Nephrology
Volume22
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Tacrolimus
Sirolimus
Immunosuppressive Agents
Kidney Transplantation
Mycophenolic Acid
Cyclosporine
Transplants
Kidney
Graft Survival
Virus Diseases
Patient Compliance
Immunosuppression
Adrenal Cortex Hormones
Hospitalization
Arm
Maintenance
Tissue Donors
Therapeutics
Infection

ASJC Scopus subject areas

  • Nephrology

Cite this

Randomized trial of immunosuppressive regimens in renal transplantation. / Guerra, Giselle; Ciancio, Gaetano; Gaynor, Jeffrey; Zarak, Alberto; Brown, Randolph; Hanson, Lois; Sageshima, Junichiro; Roth, David; Chen, Linda J; Kupin, Warren; Tueros, Lissett; Ruiz, Phillip; Livingstone, Alan; Burke, George W.

In: Journal of the American Society of Nephrology, Vol. 22, No. 9, 01.09.2011, p. 1758-1768.

Research output: Contribution to journalArticle

@article{c0c8b2a11f4a47fd9220d72216d9d6bd,
title = "Randomized trial of immunosuppressive regimens in renal transplantation",
abstract = "The optimal long-term regimen for immunosuppression for kidney transplant recipients is unknown. We conducted a randomized trial involving 150 kidney transplant recipients to compare tacrolimus/sirolimus, tacrolimus/mycophenolate mofetil (MMF), and cyclosporine/sirolimus. All patients received daclizumab induction and maintenance corticosteroids. Median follow-up was 8 yr post-transplant. Acute rejection (AR) occurred significantly less often among those treated with tacrolimus/MMF (12{\%}) than among those treated with tacrolimus/sirolimus (30{\%}) or cyclosporine/sirolimus (28{\%}). Mean estimated GFR was consistently higher in the tacrolimus/MMF arm, especially after controlling for donor age in a multivariable model during the first 36 mo (P ≲ 0.008). The rate of dying with a functioning graft was significantly higher among those treated with tacrolimus/sirolimus (26{\%}) than among those treated with tacrolimus/ MMF (12{\%}) or cyclosporine/sirolimus (4{\%}). We did not observe significant differences in actuarial graft survival at 8 yr post-transplant between the groups. Patient noncompliance seemed responsible for 45{\%} (13/29) of observed graft failures, with 11 of these occurring after 36 mo. Significantly more viral infections, protocol violations, and need for antilipid therapy occurred among patients receiving sirolimus, but we did not observe differences between the groups with regard to infections requiring hospitalization or new-onset diabetes. Taken together, these results suggest that maintenance therapy with tacrolimus/MMF is more favorable than either tacrolimus/sirolimus or cyclosporine/sirolimus.",
author = "Giselle Guerra and Gaetano Ciancio and Jeffrey Gaynor and Alberto Zarak and Randolph Brown and Lois Hanson and Junichiro Sageshima and David Roth and Chen, {Linda J} and Warren Kupin and Lissett Tueros and Phillip Ruiz and Alan Livingstone and Burke, {George W}",
year = "2011",
month = "9",
day = "1",
doi = "10.1681/ASN.2011010006",
language = "English",
volume = "22",
pages = "1758--1768",
journal = "Journal of the American Society of Nephrology",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "9",

}

TY - JOUR

T1 - Randomized trial of immunosuppressive regimens in renal transplantation

AU - Guerra, Giselle

AU - Ciancio, Gaetano

AU - Gaynor, Jeffrey

AU - Zarak, Alberto

AU - Brown, Randolph

AU - Hanson, Lois

AU - Sageshima, Junichiro

AU - Roth, David

AU - Chen, Linda J

AU - Kupin, Warren

AU - Tueros, Lissett

AU - Ruiz, Phillip

AU - Livingstone, Alan

AU - Burke, George W

PY - 2011/9/1

Y1 - 2011/9/1

N2 - The optimal long-term regimen for immunosuppression for kidney transplant recipients is unknown. We conducted a randomized trial involving 150 kidney transplant recipients to compare tacrolimus/sirolimus, tacrolimus/mycophenolate mofetil (MMF), and cyclosporine/sirolimus. All patients received daclizumab induction and maintenance corticosteroids. Median follow-up was 8 yr post-transplant. Acute rejection (AR) occurred significantly less often among those treated with tacrolimus/MMF (12%) than among those treated with tacrolimus/sirolimus (30%) or cyclosporine/sirolimus (28%). Mean estimated GFR was consistently higher in the tacrolimus/MMF arm, especially after controlling for donor age in a multivariable model during the first 36 mo (P ≲ 0.008). The rate of dying with a functioning graft was significantly higher among those treated with tacrolimus/sirolimus (26%) than among those treated with tacrolimus/ MMF (12%) or cyclosporine/sirolimus (4%). We did not observe significant differences in actuarial graft survival at 8 yr post-transplant between the groups. Patient noncompliance seemed responsible for 45% (13/29) of observed graft failures, with 11 of these occurring after 36 mo. Significantly more viral infections, protocol violations, and need for antilipid therapy occurred among patients receiving sirolimus, but we did not observe differences between the groups with regard to infections requiring hospitalization or new-onset diabetes. Taken together, these results suggest that maintenance therapy with tacrolimus/MMF is more favorable than either tacrolimus/sirolimus or cyclosporine/sirolimus.

AB - The optimal long-term regimen for immunosuppression for kidney transplant recipients is unknown. We conducted a randomized trial involving 150 kidney transplant recipients to compare tacrolimus/sirolimus, tacrolimus/mycophenolate mofetil (MMF), and cyclosporine/sirolimus. All patients received daclizumab induction and maintenance corticosteroids. Median follow-up was 8 yr post-transplant. Acute rejection (AR) occurred significantly less often among those treated with tacrolimus/MMF (12%) than among those treated with tacrolimus/sirolimus (30%) or cyclosporine/sirolimus (28%). Mean estimated GFR was consistently higher in the tacrolimus/MMF arm, especially after controlling for donor age in a multivariable model during the first 36 mo (P ≲ 0.008). The rate of dying with a functioning graft was significantly higher among those treated with tacrolimus/sirolimus (26%) than among those treated with tacrolimus/ MMF (12%) or cyclosporine/sirolimus (4%). We did not observe significant differences in actuarial graft survival at 8 yr post-transplant between the groups. Patient noncompliance seemed responsible for 45% (13/29) of observed graft failures, with 11 of these occurring after 36 mo. Significantly more viral infections, protocol violations, and need for antilipid therapy occurred among patients receiving sirolimus, but we did not observe differences between the groups with regard to infections requiring hospitalization or new-onset diabetes. Taken together, these results suggest that maintenance therapy with tacrolimus/MMF is more favorable than either tacrolimus/sirolimus or cyclosporine/sirolimus.

UR - http://www.scopus.com/inward/record.url?scp=80052317076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052317076&partnerID=8YFLogxK

U2 - 10.1681/ASN.2011010006

DO - 10.1681/ASN.2011010006

M3 - Article

C2 - 21807891

AN - SCOPUS:80052317076

VL - 22

SP - 1758

EP - 1768

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 9

ER -